HOMOLOGY MEDICINES INC (FIXX)
US4380831077 - Common Stock
Overall FIXX gets a fundamental rating of 2 out of 10. We evaluated FIXX against 588 industry peers in the Biotechnology industry. While FIXX seems to be doing ok healthwise, there are quite some concerns on its profitability. FIXX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year FIXX has reported negative net income.
FIXX had a negative operating cash flow in the past year.
FIXX had negative earnings in each of the past 5 years.
In the past 5 years FIXX always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -133.57%, FIXX is doing worse than 85.71% of the companies in the same industry.
FIXX has a Return On Equity of -154.74%. This is in the lower half of the industry: FIXX underperforms 67.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -133.57% | ||
| ROE | -154.74% | ||
| ROIC | N/A |
ROA(3y)-60.34%
ROA(5y)-52.65%
ROE(3y)-71.33%
ROE(5y)-63.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FIXX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FIXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FIXX has been increased compared to 1 year ago.
Compared to 5 years ago, FIXX has more shares outstanding
FIXX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -8.72, we must say that FIXX is in the distress zone and has some risk of bankruptcy.
FIXX's Altman-Z score of -8.72 is on the low side compared to the rest of the industry. FIXX is outperformed by 75.00% of its industry peers.
There is no outstanding debt for FIXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.72 |
ROIC/WACCN/A
WACC9.71%
2.3 Liquidity
A Current Ratio of 7.25 indicates that FIXX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.25, FIXX is in the better half of the industry, outperforming 69.56% of the companies in the same industry.
FIXX has a Quick Ratio of 7.25. This indicates that FIXX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.25, FIXX is in the better half of the industry, outperforming 69.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.25 | ||
| Quick Ratio | 7.25 |
3. Growth
3.1 Past
The earnings per share for FIXX have decreased by -3.16% in the last year.
The Revenue for FIXX has decreased by -64.06% in the past year. This is quite bad
The Revenue for FIXX have been decreasing by -26.31% on average. This is quite bad
EPS 1Y (TTM)-3.16%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q53.33%
Revenue 1Y (TTM)-64.06%
Revenue growth 3Y-24.63%
Revenue growth 5Y-26.31%
Revenue growth Q2Q-100%
3.2 Future
Based on estimates for the next years, FIXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.92% on average per year.
Based on estimates for the next years, FIXX will show a quite strong growth in Revenue. The Revenue will grow by 10.76% on average per year.
EPS Next Y64.09%
EPS Next 2Y27.87%
EPS Next 3Y9.98%
EPS Next 5Y12.92%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y18.56%
Revenue Next 5Y10.76%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FIXX. In the last year negative earnings were reported.
Also next year FIXX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.87%
EPS Next 3Y9.98%
5. Dividend
5.1 Amount
No dividends for FIXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HOMOLOGY MEDICINES INC
NASDAQ:FIXX (3/25/2024, 8:23:28 PM)
After market: 0.892 -0.04 (-4.57%)0.9347
+0.01 (+0.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap54.23M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -133.57% | ||
| ROE | -154.74% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.25 | ||
| Quick Ratio | 7.25 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-3.16%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y64.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-64.06%
Revenue growth 3Y-24.63%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y